Edition:
India

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Global Select Market

0.63USD
16 Oct 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.63
Open
$0.57
Day's High
$0.64
Day's Low
$0.57
Volume
52,160
Avg. Vol
94,958
52-wk High
$4.44
52-wk Low
$0.49

Latest Key Developments (Source: Significant Developments)

Aptevo Therapeutics Reports Continued Progress In Apvo210 And Apvo436 Clinical Trials
Friday, 26 Jul 2019 

July 25 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS CONTINUED PROGRESS IN APVO210 AND APVO436 CLINICAL TRIALS.APTEVO THERAPEUTICS INC - RECEIVES APPROVAL TO BEGIN APVO210 MULTIPLE ASCENDING DOSE (MAD) STUDY.APTEVO THERAPEUTICS INC - NO ANTI-DRUG ANTIBODIES OBSERVED IN APVO210 SAD PHASE 1 STUDY BASED ON PATIENT SAMPLES OBTAINED TO DATE.APTEVO THERAPEUTICS INC - APVO436 PHASE 1 CLINICAL STUDY PROGRESSING ON TRACK; APPROVAL RECEIVED TO BEGIN DOSING IN COHORT 4.APTEVO THERAPEUTICS INC - APVO436 PHASE 1 CLINICAL STUDY PROGRESSING ON TRACK; APPROVAL RECEIVED TO BEGIN DOSING IN COHORT 4.APTEVO THERAPEUTICS INC - LOOK FORWARD TO REPORTING RESULTS FROM MAD STUDY IN Q1 OF 2020.APTEVO - PRELIMINARY DATA SUGGEST SINGLE DOSES OF APVO210 APPEAR TO BE SAFE & WELL TOLERATED AT DOSES EQUIVALENT TO IL-10 DOSES.  Full Article

Aptevo Therapeutics Reports Q1 Loss Per Share $0.44
Thursday, 9 May 2019 

May 9 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.44.ON TARGET FOR LAUNCH OF NEW 3,000 IU IXINITY ASSAY MID-2019.APTEVO THERAPEUTICS- ADVANCES ENROLLMENT IN APVO436 & APVO210 PHASE 1 CLINICAL STUDIES; SEES TOP-LINE PRELIMINARY DATA READ-OUTS IN Q3 & Q4 2019.APTEVO HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES AS OF MARCH 31, 2019 TOTALING $44.5 MILLION.  Full Article

Aptevo Announces Stock Purchase Agreement
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS ANNOUNCES UP TO $35 MILLION COMMON STOCK PURCHASE AGREEMENT WITH LINCOLN PARK CAPITAL.APTEVO THERAPEUTICS INC - PROVIDES CAPITAL OF UP TO $35 MILLION TO APTEVO DURING 36-MONTH TERM OF AGREEMENT.APTEVO THERAPEUTICS - BELIEVE COMBINATION OF CASH, IXINITY CASH FLOW & AGREEMENT PROCEEDS POTENTIALLY PROIVDE ACCESS TO CAPITAL THROUGH H2 OF 2020.  Full Article

Aptevo Therapeutics Q3 Loss Per Share $0.56
Thursday, 15 Nov 2018 

Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.56.Q3 EARNINGS PER SHARE VIEW $-0.57 -- THOMSON REUTERS I/B/E/S.DISCONTINUES CLINICAL DEVELOPMENT OF APVO414 AND OTLERTUZUMAB; SHARPENS FOCUS ON NEXT-GENERATION ADAPTIR PIPELINE.IS ALSO PROGRESSING PLANS TO ADVANCE A SECOND CANDIDATE, APVO210, INTO CLINIC IN Q1 OF 2019.ADVANCES BISPECIFICS APVO436 AND APVO210; ON TRACK TO COMMENCE PATIENT DOSING Q4 2018 AND Q1 2019.HAD CASH, CASH EQUIVALENTS, RESTRICTED CASH, AND SHORT-TERM INVESTMENTS AS OF SEPTEMBER 30, 2018 TOTALING $45.5 MILLION.  Full Article

Aptevo Therapeutics Q1 Loss Per Share $0.63
Thursday, 10 May 2018 

Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.63.QUARTERLY TOTAL REVENUES $4.1 MILLION VERSUS $2.1 MILLION.  Full Article

Aptevo Therapeutics Reports 2017 Financial Results And Provides Business Update
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.APTEVO - ‍HAD CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 TOTALING $91.2 MILLION​.  Full Article

Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA.APTEVO THERAPEUTICS INC- ‍EXPECTS TO FILE 2 IND APPLICATIONS IN 2018 FOR 2 BISPECIFIC ANTIBODY CANDIDATES, APVO436 AND APVO210​.  Full Article

Aptevo Therapeutics files mixed shelf of up to $150 mln
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

Aptevo Therapeutics reports third quarter 2017 financial results
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics reports third quarter 2017 financial results.Q3 earnings per share $1.77.  Full Article